B3436

N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]benzamide

≥98% (HPLC), solid

• Synonyme(s) : C2-8
• Formule empirique (notation de Hill) : C₁₉H₁₄Br₂N₂O₃S
• Numéro CAS: 300670-16-0
• Poids moléculaire : 510.20
• NACRES: NA.77
• PubChem Substance ID: 24724418
• UNSPSC Code: 12352200
• MDL number: MFCD00355835
• Assay: ≥98% (HPLC)
• Form: solid

Propriétés

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• color: off-white
• solubility: DMSO: ~20 mg/mL, H₂O: insoluble
• storage temp.: 2-8°C
• SMILES string: Brc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)Nc3ccc(Br)cc3)cc1
• InChI: 1S/C19H14Br2N2O3S/c20-14-4-8-16(9-5-14)22-19(24)13-2-1-3-18(12-13)27(25,26)23-17-10-6-15(21)7-11-17/h1-12,23H,(H,22,24)
• InChI key: SJJKUNDBFWUAQB-UHFFFAOYSA-N

Description

Biochem/physiol Actions

N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl] benzamide is the first inhibitor of aggregation of the polyglutamine (polyQ) sequence of the Huntington′s Disease protein (huntingtin).

N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]benzamide is the first inhibitor of aggregation of the polyglutamine (polyQ) sequence of the Huntington′s Disease protein (huntingtin); polyQ aggregation is neurotoxic, and inhibitors of aggregation may be therapeutic in HD and other polyQ diseases; C2-8 inhibited aggregation in HD PC12 cells with an IC50 of 50nM; when administered in food, suppressed neurodegeneration in vivo in the Drosophila HD model.

Informations sur la sécurité

• pictograms: GHS07
• signalword: Warning
• hcodes: H319,H413
• pcodes: P273 - P305 + P351 + P338
• Hazard Classifications: Aquatic Chronic 4 - Eye Irrit. 2
• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves